Telix supplies Bayer with Illuccix® for global phase III prostate therapy

Telix supplies Bayer with Illuccix® for global phase III prostate therapy


Melbourne, Australia, May 7, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited TLX Telix, the Company) announced today that it has reached an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, Gallium Ga 68 Gozetotide Injection Preparation Kit)[1] for the phase III ARASTEP study ( identifier: NCT05794906). This global study evaluates the efficacy of Bayer’s androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) compared to ADT alone in hormone-sensitive prostate cancer in patients with high-risk biochemical recurrence who have no evidence of metastatic disease from conventional imaging and treatment a positive PSMA PET/CT[2] at the baseline.

The study will enroll up to 750 patients at different sites such as in Europe, Japan And The United States. The more sensitive PSMA imaging can identify prostate cancer lesions that are undetectable by traditional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and bone scans.

Telix Chief Medical Officer, Dr Colin Hayward stated, “We are pleased to include Bayer and a number of clinical centers in this important study, which reflects Telix’s unique commitment to bringing advanced prostate cancer imaging to the world, using this imaging modality to move beyond diagnosis to a disease management tool.” .”

About Bayer AG

Bayer is a global company with core competencies in the life science areas of health and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to meet the grand challenges of a growing and aging world population. Bayer is committed to driving sustainable development and making a positive impact with its businesses. At the same time, the Group wants to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality…


Source story

More to explorer